Remove Clinical Development Remove Clinical Trials Remove DNA Remove Recombinant DNA Technology
article thumbnail

Amivantamab by Johnson & Johnson for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Colorectal Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.